Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 oct. 2018 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin
02 oct. 2018 08h30 HE
|
Dermira, Inc.
Mr. Siriano invites the millions of people living with hyperhidrosis in the U.S. to share their ‘sweat stories’ MENLO PARK, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a...
Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis
01 oct. 2018 07h30 HE
|
Dermira, Inc.
QBREXZA is now available in retail and community pharmacies across the United StatesQBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for people 9 years...
Dermira to Present at Cantor 2018 Global Healthcare Conference
25 sept. 2018 08h00 HE
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress
13 sept. 2018 06h00 HE
|
Dermira, Inc.
Primary axillary hyperhidrosis is a medical condition that can occur in the pediatric population and is largely undertreated and under-diagnosedPost-hoc analysis of ARIDO long-term safety study...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 sept. 2018 16h02 HE
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis
05 sept. 2018 07h30 HE
|
Dermira, Inc.
Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRxCompany announces DermiraConnect, a new patient access program that will provide patients broad access to...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 août 2018 20h14 HE
|
Dermira, Inc.
MENLO PARK, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06 août 2018 16h01 HE
|
Dermira, Inc.
- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018- QBREXZA expected to be available nationwide in pharmacies beginning in October 2018-...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 juil. 2018 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...